Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC)

Oh, D-Y; Kim, Y.-J.; Han, Sang-Sook; Choi, In Suk; Kim, J. H.; Kim, D.-W.; Im, Stoppa; Kim, T.-Y.; Heo, Dae-Seog; Bang, Yunkyu; Kim, N. K.

doi:10.1200/jco.2005.23.16_suppl.3720

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th e same is true for standard FOLFOX therapy [94]. If required, treatment tolerance can be further optimized by bifractionated drug administration [103] or dose reduction [104].…”

Section: Should Our Treatment Approach Be Different For Elderly Patiementioning

confidence: 98%

“…Th e available evidence from the FFCD, FOCUS 2 and GERICO trials seems to support the idea of starting with reduced doses and increasing them in the absence of toxicity. In the case of (unexpected) poor tolerance of oxaliplatin-based chemotherapy, delivery of the platinum analogue over 2 days [103] should be considered [104]. (3) Is there a regimen that minimizes toxicity while retaining effi cacy?…”

Section: Should Our Treatment Approach Be Different For Elderly Patiementioning

confidence: 99%

See 1 more Smart Citation

Consensus on the medical treatment of colon cancer

Kornek

Scheithauer

Anghel

et al. 2008

memo

View full text Add to dashboard Cite

Purpose: To throw light on some of the issues in the choice of therapy for patients with metastatic colorectal cancer (mCRC) and to provide consensus recommendations on which combination(s) and sequence(s) of systemic therapy to be used in diff erent treatment situations.Material and methods: An expert panel comprising clinicians and the UK with expertise in medical oncology, clinical oncology, surgery and dermatology, and specialist knowledge of the treatment of patients with CRC was convened by the Central European Cooperative Oncology Group (CECOG) in Vienna in 2007. Members were then asked to agree on a consensus statement following a period of discussion at the end of a series of presentations.Results and conclusions: Th e consensus recommendations for the state-of-the-art treatment of colon cancer arrived at by an "expert panel" of clinicians were that: oral 5-fl uorouracil (5-FU) prodrugs or protracted intravenous infusion of the antimetabolite are preferable to bolus administration; all active drugs (fl uoropyrimidines, irinotecan, oxaliplatin, bevacizumab, cetuximab) should be used during strategic patient management; after neoadjuvant treatment and consultation of an interdisciplinary team, surgery should be considered for metastatic disease wherever possible and "fi t" elderly patients should not be denied the same treatment as younger patients. memo magazine of european medical oncology memo Recommendations for the treatment of metastatic colon cancer 2/2008 consensus report 79

show abstract

“…Th e same is true for standard FOLFOX therapy [94]. If required, treatment tolerance can be further optimized by bifractionated drug administration [103] or dose reduction [104].…”

Section: Should Our Treatment Approach Be Different For Elderly Patiementioning

confidence: 98%

Section: Should Our Treatment Approach Be Different For Elderly Patiementioning

confidence: 99%

Consensus on the medical treatment of colon cancer

Kornek

Scheithauer

Anghel

et al. 2008

memo

View full text Add to dashboard Cite

show abstract

Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient

Power

Lichtman

2008

Seminars in Colon and Rectal Surgery

View full text Add to dashboard Cite

Managing Older Patients With Colorectal Cancer

Sanoff

Bleiberg

Goldberg

2007

JCO

View full text Add to dashboard Cite

Colorectal cancer (CRC) is predominantly a disease of older persons, and our population is aging. Physicians and their older patients commonly face the dilemma of whether or not to give/receive systemic chemotherapy for CRC. Evidence supports the safety and efficacy of systemic chemotherapy in fit older patients motivated enough to enroll onto clinical trials. Conversely, frail older patients are more likely to suffer adverse outcomes when faced with stressors and may not benefit from chemotherapy. However, the majority of patients are neither fit nor frail, and current evidence is insufficient to either quantify or qualify the benefit of chemotherapy for this intermediate group of patients. Thus, treatment decisions must be individualized based on each older person's physical state (eg, their function and degree of comorbidity) and values. Despite a growing body of data, a great deal of work is still needed to establish optimal strategies to care for patients diagnosed with cancer later in life.

show abstract

Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC)

Cited by 4 publications

References 0 publications

Consensus on the medical treatment of colon cancer

Consensus on the medical treatment of colon cancer

Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient

Managing Older Patients With Colorectal Cancer

Contact Info

Product

Resources

About